Type 2 diabetes prevention through hormone sensitive lipase inhibition: elongase ELOVL6 at the center of attention

P. Morigny (1) , M. Houssier (1) , E. Mouisel (1) , A. Mairal (1) , S. Caspar-Bauguil (1) , Geneviève Tavernier (1) , S. Virtue (2) , Hervé Guillou (3) , V. Stich (4) , P. Arner (5) , M. Ryden (5) , A. Vidal-Puig (2) , Hubert Vidal (6) , C. Postic (7) , D. Langin (1)

1 I2MC - Institut des Maladies Métaboliques et Cardiovasculaires
2 Metabolic Research Laboratories
3 ToxAlim-TIM - Toxicologie Intégrative & Métabolisme
4 UK - Univerzita Karlova [Praha, Česká republika] = Charles University [Prague, Czech Republic]
5 Karolinska Institutet [Stockholm]
6 CarMeN - Cardiovasculaire, métabolisme, diabétologie et nutrition
7 IC UM3 (UMR 8104 / U1016) - Institut Cochin

Domaines: Sciences du Vivant [q-bio]

P. Morigny, M. Houssier, E. Mouisel, A. Mairal, S. Caspar-Bauguil, et al.. Type 2 diabetes prevention through hormone sensitive lipase inhibition: elongase ELOVL6 at the center of attention. Diabetologia, 2017, 60, pp.S249. ⟨hal-02624062⟩